Literature DB >> 31798392

Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).

Diana Lüftner1, Ingo Bauerfeind2, Michael Braun3, Sara Y Brucker4, Peter A Fasching5, Ricardo Felberbaum6, Friederike Hagemann7, Renate Haidinger8, Nadia Harbeck7, Arnd Hönig9, Jens Huober10, Christian Jackisch11, Hans-Christian Kolberg12, Cornelia Kolberg-Liedtke13, Thorsten Kühn14, Nicolai Maass15, Toralf Reimer16, Andreas Schneeweiss17, Eva Schumacher-Wulf18, Florian Schütz19, Christoph Thomssen20, Michael Untch21, Rachel Wuerstlein7, Marc Thill22.   

Abstract

A German working group of leading breast cancer experts have discussed the votes at the International St. Gallen Consensus Conference in Vienna for the treatment of primary breast cancer with regard to the German AGO (Ar-beitsgemeinschaft Gynäkologische Onkologie) recommendations for clinical practice in Germany. Three of the German breast cancer experts were also members of this year's St. Gallen panel. Comparing the St. Gallen recommendations with the annually updated treatment recommendations of the Gynecological Oncology Working Group (AGO Mamma 2019) and the German S3 Guideline is useful, because the recommendations of the St. Gallen panel are based on expert opinions of different countries and disciplines. The focus of this article is on systemic therapy. The motto of this year's 16th St. Gallen Consensus Conference was "Estimating the magnitude of clinical benefit." The rationale behind this motto is that, for every treatment decision, a benefit-risk assessment must be taken into consideration for each patient.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Axilla; Early breast cancer; Locoregional therapy; Neoadjuvant treatment; St. Gallen Consensus Conference 2019; Systemic therapy

Year:  2019        PMID: 31798392      PMCID: PMC6883436          DOI: 10.1159/000502603

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  19 in total

1.  Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Michael Gnant; Georg Pfeiler; Peter C Dubsky; Michael Hubalek; Richard Greil; Raimund Jakesz; Viktor Wette; Marija Balic; Ferdinand Haslbauer; Elisabeth Melbinger; Vesna Bjelic-Radisic; Silvia Artner-Matuschek; Florian Fitzal; Christian Marth; Paul Sevelda; Brigitte Mlineritsch; Günther G Steger; Diether Manfreda; Ruth Exner; Daniel Egle; Jonas Bergh; Franz Kainberger; Susan Talbot; Douglas Warner; Christian Fesl; Christian F Singer
Journal:  Lancet       Date:  2015-05-31       Impact factor: 79.321

2.  West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Authors:  Oleg Gluz; Ulrike A Nitz; Matthias Christgen; Ronald E Kates; Steven Shak; Michael Clemens; Stefan Kraemer; Bahriye Aktas; Sherko Kuemmel; Toralf Reimer; Manfred Kusche; Volker Heyl; Fatemeh Lorenz-Salehi; Marianne Just; Daniel Hofmann; Tom Degenhardt; Cornelia Liedtke; Christer Svedman; Rachel Wuerstlein; Hans H Kreipe; Nadia Harbeck
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

3.  Exemestane with ovarian suppression in premenopausal breast cancer.

Authors:  Olivia Pagani; Meredith M Regan; Prudence A Francis
Journal:  N Engl J Med       Date:  2014-10-02       Impact factor: 91.245

4.  Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Miguel Martin; Frankie A Holmes; Bent Ejlertsen; Suzette Delaloge; Beverly Moy; Hiroji Iwata; Gunter von Minckwitz; Stephen K L Chia; Janine Mansi; Carlos H Barrios; Michael Gnant; Zorica Tomašević; Neelima Denduluri; Robert Šeparović; Erhan Gokmen; Anna Bashford; Manuel Ruiz Borrego; Sung-Bae Kim; Erik Hugger Jakobsen; Audrone Ciceniene; Kenichi Inoue; Friedrich Overkamp; Joan B Heijns; Anne C Armstrong; John S Link; Anil Abraham Joy; Richard Bryce; Alvin Wong; Susan Moran; Bin Yao; Feng Xu; Alan Auerbach; Marc Buyse; Arlene Chan
Journal:  Lancet Oncol       Date:  2017-11-13       Impact factor: 41.316

5.  Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

Authors:  Sibylle Loibl; Joyce O'Shaughnessy; Michael Untch; William M Sikov; Hope S Rugo; Mark D McKee; Jens Huober; Mehra Golshan; Gunter von Minckwitz; David Maag; Danielle Sullivan; Norman Wolmark; Kristi McIntyre; Jose J Ponce Lorenzo; Otto Metzger Filho; Priya Rastogi; W Fraser Symmans; Xuan Liu; Charles E Geyer
Journal:  Lancet Oncol       Date:  2018-02-28       Impact factor: 41.316

6.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Authors:  Fatima Cardoso; Laura J van't Veer; Jan Bogaerts; Leen Slaets; Giuseppe Viale; Suzette Delaloge; Jean-Yves Pierga; Etienne Brain; Sylvain Causeret; Mauro DeLorenzi; Annuska M Glas; Vassilis Golfinopoulos; Theodora Goulioti; Susan Knox; Erika Matos; Bart Meulemans; Peter A Neijenhuis; Ulrike Nitz; Rodolfo Passalacqua; Peter Ravdin; Isabel T Rubio; Mahasti Saghatchian; Tineke J Smilde; Christos Sotiriou; Lisette Stork; Carolyn Straehle; Geraldine Thomas; Alastair M Thompson; Jacobus M van der Hoeven; Peter Vuylsteke; René Bernards; Konstantinos Tryfonidis; Emiel Rutgers; Martine Piccart
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

Review 7.  The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.

Authors:  Fausto Petrelli; Andrea Coinu; Karen Borgonovo; Mary Cabiddu; Mara Ghilardi; Veronica Lonati; Sandro Barni
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

8.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Edith A Perez; John A Olson; JoAnne Zujewski; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; James N Atkins; Jeffrey L Berenberg; George W Sledge
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

10.  Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.

Authors:  Eric Hahnen; Bianca Lederer; Jan Hauke; Sibylle Loibl; Sandra Kröber; Andreas Schneeweiss; Carsten Denkert; Peter A Fasching; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Sherko Kümmel; Christian Schem; Guido Neidhardt; Jens Huober; Kerstin Rhiem; Serban Costa; Janine Altmüller; Claus Hanusch; Holger Thiele; Volkmar Müller; Peter Nürnberg; Thomas Karn; Valentina Nekljudova; Michael Untch; Gunter von Minckwitz; Rita K Schmutzler
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

View more
  6 in total

1.  Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer.

Authors:  Qing Li; Jiani Wang; Yuxin Mu; Tongtong Zhang; Ying Han; Jiayu Wang; Qiao Li; Yang Luo; Fei Ma; Ying Fan; Pin Zhang; Binghe Xu
Journal:  Chin J Cancer Res       Date:  2020-08       Impact factor: 5.087

2.  Reply to Ivica Ratosa et al. Comment on: "Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study".

Authors:  E Pons-Tostivint; P Grosclaude; L Daubisse-Marliac
Journal:  Breast       Date:  2020-06-20       Impact factor: 4.380

Review 3.  Genomic Signatures in Luminal Breast Cancer.

Authors:  Julian Puppe; Tabea Seifert; Christian Eichler; Henryk Pilch; Peter Mallmann; Wolfram Malter
Journal:  Breast Care (Basel)       Date:  2020-07-21       Impact factor: 2.860

4.  Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database.

Authors:  Ran Cheng; Xiangyi Kong; Xiangyu Wang; Yi Fang; Jing Wang
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

Review 5.  Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic.

Authors:  Tabitha Tse; Sandeep Sehdev; Jean Seely; Denis H Gravel; Mark Clemons; Erin Cordeiro; Angel Arnaout
Journal:  Curr Oncol       Date:  2021-03-24       Impact factor: 3.677

6.  The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.

Authors:  Baojuan Han; Lina Dong; Jing Zhou; Yan Yang; Jiaxun Guo; Qijia Xuan; Kun Gao; Zhenguo Xu; Wanting Lei; Jingxuan Wang; Qingyuan Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-03-10       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.